Australia's most trusted
source of pharma news
Sunday, 29 September 2024
Posted 24 June 2024 AM
Pfizer could turn the tables on Sanofi after the PBAC recommended listing its RSV vaccine Abrysvo on the National Immunisation Program during its May intracycle meeting.
The decision marks the first ever RSV vaccine to be recommended for national funding in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.